Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors for its primary biliary/gastrointestinal excretion rather than renal clearance.
## Primary Indications
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
## Adult Dosing
5 mg orally once daily. May be taken with or without food.
## Pediatric Dosing
Safety and efficacy have not been established in pediatric patients (under 18 years). Use is not recommended.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment required.
* **Hepatic Impairment:** No dosage adjustment required.
* **Concomitant use with Insulin/Secretagogues:** Consider a lower dose of the insulin secretagogue (e.g., sulfonylurea) or insulin to reduce the risk of hypoglycemia.
## Contraindications
* Hypersensitivity to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
* History of pancreatitis.
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with insulin/sulfonylureas).
* **Serious:** Acute pancreatitis (including fatal cases), bullous pemphigoid (requires discontinuation), severe joint pain (arthralgia), and hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., rifampin):** May decrease linagliptin efficacy. If combined, monitor glycemic control closely; switching to an alternative agent may be necessary.
* **Insulin/Sulfonylureas:** Increased risk of hypoglycemia.
## Monitoring
* **Glycemic Control:** HbA1c (typically every 3–6 months) and periodic blood glucose monitoring.
* **Pancreatitis:** Monitor for persistent, severe abdominal pain.
* **Skin:** Monitor for blistering or erosions.
## Clinical Pearls
* Linagliptin is the only DPP-4 inhibitor that does not require renal dose adjustment, making it a convenient choice for patients with chronic kidney disease.
* Unlike GLP-1 receptor agonists, linagliptin is weight-neutral and carries a lower risk of gastrointestinal side effects.
* If pancreatitis is suspected, discontinue the drug immediately and do not restart.
* The risk of bullous pemphigoid may necessitate withdrawal of therapy if severe skin lesions develop.
***
**Educational Disclaimer:** This information is for educational purposes only. Always consult the most current official prescribing information (package insert) and institutional clinical guidelines before prescribing or administering medication. Clinical judgement should be applied based on the individual patient's status.
